Irritable Bowel Syndrome Segment, by Application to Account Largest Share in Gastrointestinal Drugs Market during 2023-2031
According to our new research study on "Gastrointestinal Drugs Market Forecast to 2031 - Global Analysis - by Drug Class, Application, Route of Administration, Distribution Channel, and Geography," the market was valued at US$ 59,713.68 million in 2023 and is projected to reach US$ 106,304.81 million by 2031; it is expected to register a CAGR of 7.3% during 2023-2031. The gastrointestinal drugs market growth is attributed to the increasing prevalence gastrointestinal diseases and increasing developments of biologics for gastrointestinal diseases. Strategic initiatives by gastrointestinal drugs market players are likely to offer opportunities for market growth. The gastrointestinal drugs market report emphasizes the key factors driving the market and showcases the developments of prominent players.
Gastrointestinal diseases are becoming prevalent worldwide. Many research institutes are offering funding to accelerate the discovery of new methods for the treatment of gastrointestinal disorders. For instance, Yale School of Medicine receives over US$ 8 million per year in research funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDKK). The primary research areas include understanding mechanisms responsible for pancreatic inflammation and pancreatitis genetics and immunobiology of inflammatory bowel disease, as well as complications and treatment of IBD, cirrhosis, viral hepatitis, and liver cancer. In addition, the UNC School of Medicine, which is engaged in the advancement of understanding the impacts of gastrointestinal and liver diseases and developing new treatments, accounted for a gastrointestinal research funding that exceeds US$ 20 million annually. The UNC Center for Functional Gastrointestinal and Motility Disorders has been a top?global center for research on constipation, irritable bowel syndrome, and fecal incontinence. The research includes translational studies on the stool microbiome and genetic contributions to IBS, the development and validation of diagnostic criteria, clinical studies of the physiological and psychological mechanisms for symptoms, epidemiological studies, and systems-based research on healthcare delivery.
Apart from this, the American Gastroenterological Association Research Foundation provides approximately US$ 3 million in research grants yearly to investigators in the fields of gastroenterology and hepatology. In June 2023, the American Gastroenterological Association and American College of Gastroenterology invested in Oshi Health to accelerate the adoption of hybrid digestive healthcare. Oshi Health provides diagnosis and integrated care for digestive conditions. By funding various researchers, the foundation is also supporting the discovery of new tools and treatments for people suffering from digestive problems.
Gastrointestinal clinical research has evolved over the past decade. The use of Artificial intelligence (AI) is becoming increasingly common in many areas, particularly in the medical field. AI has the potential to revolutionize the design of gastrointestinal clinical research. The integration of AI algorithms enables researchers to extract essential insights from enormous patient data sets, resulting in more accurate and personalized treatments for gastrointestinal conditions. Further, machine learning algorithms help analyze patient data, genetic profiles, and treatment outcomes to find predictive markers for therapy response. By precisely identifying patient subgroups that are most likely to benefit from particular interventions, researchers can optimize treatment strategies and enhance patient outcomes.
AI-powered image analysis has the potential to transform the field of diagnostic imaging in gastrointestinal medicine. Researchers can examine medical images, such as CT scans or endoscopic images, to detect and classify abnormalities with high accuracy by using deep learning algorithms. This technology facilitates the early detection and characterization of gastrointestinal lesions, enabling timely interventions and improving patient prognosis. For example, studies have shown the efficacy of AI algorithms in diagnosing and characterizing colorectal polyps during colonoscopy, reducing the need for unnecessary surgeries. With a US$ 98,700 grant from the Newcastle Permanent Charitable Foundation on research, researchers are able to utilize AI to develop new therapies for IBD and ulcerative colitis. The microbiome and intestinal stem cells are two key components that are significant drivers of IBD but are not targeted by current therapies. identifying therapies from the gut microbiome is a complex undertaking with vast amounts of data, which is why applying AI in such research helps a lot, as it can recognize patterns in enormous amounts of data. AI also enhances the quality of not only the diagnostic process but also of individualized therapeutic strategies.
Based on type, the gastrointestinal drugs market is segmented into biologics, antidiarrheal and laxatives, acid neutralizers, anti-inflammatory drugs, antiemetic and antinauseants, and others. The biologics segment held a larger gastrointestinal drugs market share in 2023; however, the antidiarrheal and laxatives segment is expected to register a higher CAGR during 2023-2031.
Based on Application, the market is segmented into irritable bowel syndrome, inflammatory ulcerative colitis, Crohn's disease, gastroenteritis, celiac disease, and others. The irritable bowel syndrome segment held the largest gastrointestinal drugs market share in 2023, and gastroenteritis segment is estimated to register the highest CAGR during 2023-2031. Gastroenteritis or stomach flu is the irritation and inflammation of the digestive tract caused by a viral, bacterial, or parasitic infection with symptoms such as diarrhea, vomiting, nausea, and abdominal pain. The most common cause of viral gastroenteritis is norovirus and rotavirus. According to the Centers for Disease Control and Prevention (CDC), as of 2024, norovirus caused approximately 685 million cases of acute gastroenteritis worldwide, making it the most common cause of acute gastroenteritis. According to the same source, 200 million cases are diagnosed among children under 5 years of age, leading to an estimated 50,000 child deaths every year, mostly in developing countries. Further, every year, norovirus treatment is estimated to cost US$ 60 billion globally.
Sanofi SA, GSK Plc, Johnson & Johnson, Bausch Health Companies Inc, AstraZeneca Plc, Takeda Pharmaceutical Co Ltd, AbbVie Inc, Bayer AG, Celltrion Inc, and Pfizer Inc. are among the leading companies operating in the global gastrointestinal drugs market.
Companies operating in the gastrointestinal drugs market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the gastrointestinal drugs market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall gastrointestinal drugs market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com